Amphetamines and related drugs in motor recovery after stroke

Physical Medicine and Rehabilitation Clinics of North America

Volumn 14, Issue 1 SUPPL., 2003, Pages

  Goldstein, Larry B ^a,b,c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DURHAM VA MEDICAL CENTER   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CLONIDINE; DOPAMINE RECEPTOR BLOCKING AGENT; DROPERIDOL; FLUANISONE; HALOPERIDOL; IDAZOXAN; LEVODOPA; METHYLPHENIDATE; MUSCIMOL; NEUROTRANSMITTER; NORADRENALIN; PHENOXYBENZAMINE; PHENTERMINE; PHENYLPROPANOLAMINE; PHENYTOIN; PLACEBO; PRAZOSIN; SCOPOLAMINE; YOHIMBINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; APHASIA; BRAIN INJURY; CAT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DECORTICATION; DEPTH PERCEPTION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; FOLLOW UP; HUMAN; LABORATORY; MOTOR PERFORMANCE; NEUROPROTECTION; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAT; SCORING SYSTEM; STEREOISOMERISM; STEREOSCOPIC VISION; STROKE; TECHNIQUE; TREATMENT INDICATION; TREATMENT OUTCOME;

CENTRAL NERVOUS SYSTEM STIMULANTS; CEREBROVASCULAR ACCIDENT; DEXTROAMPHETAMINE; HUMANS; METHYLPHENIDATE; MOTOR CORTEX; MOVEMENT DISORDERS; RANDOMIZED CONTROLLED TRIALS;

EID: 0037325286     PISSN: 10479651     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1047-9651(02)00060-8     Document Type: Conference Paper

References (73)

1. Duncan PW, Goldstein LB, Matchar D, et al. Measurement of motor recovery after stroke. Outcome assessment and sample size requirements. Stroke 1992;23:1084-9.
2. Kinsella G, Ford B. Acute recovery patterns in stroke patients. Med J Aust 1980;2:662-6.
3. Loewen SC, Anderson BA. Predictors of stroke outcome using objective measurement scales. Stroke 1990;21:78-81.
4. Newman M. The process of recovery after stroke. Stroke 1972;3:702-10.
5. Wade DT, Langton HR, Wood VA, et al. The hemiplegic arm after stroke: measurement and recovery. J Neurol Neurosurg Psychiatry 1983;46:521-4.
6. Wade DT, Wood VA, Hewer RL. Recovery after stroke - the first three months. J Neurol Neurosurg Psychiatry 1985;48:7-13.
7. Macht MB. Effects of D-amphetamine on hemi-decorticate, decorticate, and decerebrate cats. Am J Physiol 1950;163:731-2.
8. Maling HM, Acheson GH. Righting and other postural activity in low-decerebrate and in spinal cats after D-amphetamine. J Neurophysiol 1946;9:379-86.
9. Fuxe K, Ungerstedt U. Histochemical, biochemical and functional studies on central monoamine neurons after acute and chronic amphetamine administration. In: Costa E, Garattini S, editors. Amphetamines and related compounds. New York: Raven Press; 1970. p. 257-88.
10. Innes IR, Nickerson M. Norepinephrine, epinephrine, and the sympathomimetic amines. In: Goodman LS, Gilman AG, Gilman A, et al, editors. The pharmacological basis of therapeutics. 5th edition. New York: Macmillan Publishing Company; 1985. p. 477-513.
11. Mathew RJ, Wilson WH. Dextroamphetamine-induced changes in regional cerebral blood flow. Psychopharmacology (Berl) 1985;87:298-302.
12. Finklestein SP, Fisher M, Furlan AJ, et al. Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke Therapy Academic Industry Roundtable (STAIR). Stroke 1999;30:2752-8.
13. Feeney DM, Sutton RL. Pharmacotherapy for recovery of function after brain injury. CRC Critical Reviews in Neurobiology 1987;3:135-97.
14. Feeney DM, Sutton RL. Catecholamines and recovery of function after brain damage. In: Stein DG, Sabel BA, editors. Pharmacological approaches to the treatment of brain and spinal cord injury. New York: Plenum Publishing; 1988. p. 121-42.
15. Goldstein LB. Basic and clinical studies of pharmacologic effects on recovery from brain injury. Journal of Neural Transplantation Plasticity 1993;4:175-92.
16. Goldstein LB. Pharmacology of recovery after stroke. Stroke 1990;21(Suppl 3):139-42.
17. Feeney DM, Hovda DA. Reinstatement of binocular depth perception by amphetamine and visual experience after visual cortex ablation. Brain Res 1985;342:352-6.
18. Goldstein LB. Pharmacologic modulation of recovery after stroke: clinical data. J Neurol Rehab 1991;5:129-40.
19. Goldstein LB. Drugs and stroke recovery. Neurology 1996;46:1187-8.
20. Johansen FF, Diemer NH. Enhancement of GABA neurotransmission after cerebral ischemia in the rat reduces loss of hippocampal CA1 pyramidal cells. Acta Neurol Scand 1991;84:1-6.
21. Schwartz-Bloom RD, McDonough KJ, Chase PJ, et al. Long-term neuroprotection by benzodiazepine full versus partial agonists after transient cerebral ischemia in the gerbil. J Cereb Blood Flow Metab 1998;18:548-58.
22. Schwartz RD, Huff RA, Yu X, et al. Postischemic diazepam is neuroprotective in the gerbil hippocampus. Brain Res 1994;647:153-60.
23. Schwartz RD, Yu X, Katzman MR, et al. Diazepam, given postischemia, protects selectively vulnerable neurons in the rat hippocampus and striatum. J Neurosci 1995;15:529-39.
24. Smith AL, Hoff JT, Nielsen SL, et al. Barbiturate protection in acute focal cerebral ischemia. Stroke 1974;5:1-7.
25. Sternau LL, Lust WD, Ricci AJ, et al. Role for γ-aminobutyric acid in selective vulnerability in gerbils. Stroke 1989;20:281-7.
26. Boxer PA, Cordon JJ, Mann ME, et al. Comparison of phenytoin with noncompetitive N-methyl-D-aspartate antagonists in a model of focal brain ischemia in the rat. Stroke 1990;21(Suppl 3):47-51.
27. Lyden P, Lonzo L, Nunez S. Combination chemotherapy extends the therapeutic window to 60 minutes after stroke. J Neurotrauma 1995;12:223-30.
28. Lyden PD, Hedges B. Protective effect of synaptic inhibition during cerebral ischemia in rats and rabbits. Stroke 1992;23:1463-70.
29. Lyden PD, Lonzo L. Combination therapy protects ischemic brain in rats: a glutamate antagonist plus a γ-aminobutyric acid agonist. Stroke 1994;25:189-96.
30. Schallert T, Hernandez TD, Barth TM. Recovery of function after brain damage: severe and chronic disruption by diazepam. Brain Res 1986;379:104-11.
31. Hernandez TD, Holling LC. Disruption of behavioral recovery by the anti-convulsant phenobarbital. Brain Res 1994;635:300-6.
32. Montañez S, Kline AE, Gasser TA, et al. Phenobarbital administration directed against kindled seizures delays functional recovery following brain insult. Brain Res 2000;860:29-40.
33. Brailowsky S, Knight RT, Efron R. Phenytoin increases the severity of cortical hemiplegia in rats. Brain Res 1986;376:71-7.
34. Hayes RL, Lyeth BG, Dixon CE, et al. Cholinergic antagonist reduces neurologic deficits following cerebral concussion in the rat. J Cereb Blood Flow Metab 1985;5(Suppl 1):S395-6.
35. Lyeth BG, Ray M, Hamm RJ, et al. Postinjury scopolamine administration in experimental traumatic brain injury. Brain Res 1992;569:281-6.
36. Saponjic RM, Hoane MR, Barbay S, et al. Scopolamine facilitates recovery of function following unilateral electrolytic sensorimotor cortex lesions in the rat. Restor Neurol Neurosci 1995;8:205-12.
37. De Ryck M, Duytschaever H, Janssen PAJ. Ionic channels, cholinergic mechanisms, and recovery of sensorimotor function after neocortical infarcts in rats. Stroke 1990; 21(Suppl 3):158-63.
38. Feeney DM, Gonzalez A, Law WA. Amphetamine, haloperidol, and experience interact to affect the rate of recovery after motor cortex injury. Science 1982;217:855-7.
39. Van Hasselt P. Effect of butyrophenones on motor function in rats after recovery from brain damage. Neuropharmacology 1973;12:245-7.
40. Goldstein LB, Davis JN. Post-lesion practice and amphetamine-facilitated recovery of beam-walking in the rat. Restor Neurol Neurosci 1990;1:311-4.
41. Hovda DA, Sutton RL, Feeney DM. Amphetamine-induced recovery of visual cliff performance after bilateral visual cortex ablation in cats: measurements of depth perception thresholds. Behav Neurosci 1989;103:574-84.
42. Goldstein LB, Davis JN. Beam-walking in rats: studies towards developing an animal model of functional recovery after brain injury. J Neurosci Methods 1990;31:101-7.
43. Boyeson MG, Callister TR, Cavazos JE. Biochemical and behavioral effects of a sensorimotor cortex injury in rats pretreated with the noradrenergic neurotoxin DSP-4. Behav Neurosci 1992;106:964-73.
44. Goldstein LB, Coviello A, Miller GD, et al. Norepinephrine depletion impairs motor recovery following sensorimotor cortex injury in the rat. Restor Neurol Neurosci 1991;3: 41-7.
45. Boyeson MG, Feeney DM. Intraventricular norepinephrine facilitates motor recovery following sensorimotor cortex injury. Pharmacol Biochem Behav 1990;35:497-501.
46. Pickel VM, Segal M, Bloom F. A radioautographic study of the efferent pathways of the nucleus locus coeruleus. J Comp Neurol 1974;155:15-42.
47. Ungerstedt U. Stereotaxic mapping of the monoamine pathways in rat brain. Acta Physiol Scand 1971;367(Suppl):1-48.
48. Boyeson MG, Krobert KA, Grade CM, et al. Unilateral, but not bilateral, locus coeruleus lesions facilitate recovery from sensorimotor cortex injury. Pharmacol Biochem Behav 1992;43:771-7.
49. Goldstein LB. Effects of bilateral and unilateral locus coeruleus lesions on beam-walking recovery after subsequent unilateral sensorimotor cortex suction-ablation in the rat. Restor Neurol Neurosci 1997;11:55-63.
50. Goldstein LB, Bullman S. Effects of dorsal noradrenergic bundle lesions on recovery after sensorimotor cortex injury. Pharmacol Biochem Behav 1997;58:1151-7.
51. Hovda DA, Bailey B, Montoya S, et al. Phentermine accelerates recovery of function after motor cortex injury in rats and cats. Federation of American Societies for Experimental Biology 1983;42:1157.
52. Kline AE, Chen MJ, Tso-Olivas DY, et al. Methylphenidate treatment following ablation-induced hemiplegia in rat: experience during drug action alters effects on recovery of function. Pharmacol Biochem Behav 1994;48:773-9.
53. Goldstein LB. Amphetamine-facilitated functional recovery after stroke. In: Ginsberg MD, Dietrich WD, editors. Cerebrovascular diseases. Sixteenth research (Princeton) conference. New York: Raven Press; 1989. p. 303-8.
54. Goldstein LB, Poe HV, Davis JN. An animal model of recovery of function after stroke: facilitation of recovery by an α2-adrenergic receptor antagonist. Ann Neurol 1989;26: 157-89.
55. Sutton RL, Feeney DM. α-Noradrenergic agonists and antagonists affect recovery and maintenance of beam-walking ability after sensorimotor cortex ablation in the rat. Restor Neurol Neurosci 1992;4:1-11.
56. Weaver MS, Farmer LJ, Feeney DM. Norepinephrine receptor agonists and antagonists influence rate and maintenance of recovery of function after sensorimotor cortex contusion in the rat. Soc Neurosci Abstr 1987;13:477.
57. Stephens J, Goldberg G, Demopoulos JT. Clonidine reinstates deficits following recovery from sensorimotor cortex lesion in rats. Arch Phys Med Rehabil 1986;67:666-7.
58. Feeney DM, Westerberg VS. Norepinephrine and brain damage: alpha noradrenergic pharmacology alters functional recovery after cortical trauma. Canadian Journal of Psychology 1990;44:233-52.
59. Hovda DA, Feeney DM, Salo AA, et al. Phenoxybenzamine but not haloperidol reinstates all motor and sensory deficits in cats fully recovered from sensorimotor cortex ablations. Society for Neuroscience Abstracts 1983;9:1002.
60. Goldstein LB, Davis JN. Physician prescribing patterns following hospital admission for ischemic cerebrovascular disease. Neurology 1988;38:1806-9.
61. Goldstein LB, Matchar DB, Morgenlander JC, et al. Influence of drugs on the recovery of sensorimotor function after stroke. J Neurol Rehab 1990;4:137-44.
62. Goldstein LB. Sygen in Acute Stroke Study Investigators: common drugs may influence motor recovery after stroke. Neurology 1995;45:865-71.
63. Crisostomo EA, Duncan PW, Propst MA, et al. Evidence that amphetamine with physical therapy promotes recovery of motor function in stroke patients. Ann Neurol 1988;23:94-7.
64. Reding MJ, Solomon B, Borucki SJ. Effect of dextroamphetamine on motor recovery after stroke. Neurology 1995;45(suppl 4):A222.
65. Walker-Batson D, Smith P, Curtis S, et al. Amphetamine paired with physical therapy accelerates motor recovery after stroke - further evidence. Stroke 1995;26:2254-9.
66. Hovda DA, Feeney DM. Amphetamine with experience promotes recovery of locomotor function after unilateral frontal cortex injury in the cat. Brain Res 1984;298:358-61.
67. Mas J-L, Arquizan C, Lamy C, et al. Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med 2001;345:1740-6.
68. Walker-Batson D, Unwin H, Curtis S, et al. Use of amphetamine in the treatment of aphasia. Restor Neurol Neurosci 1992;4:47-50.
69. Walker-Batson D, Curtis S, Natarajan R, et al. A double-blind, placebo-controlled study of the use of amphetamine in the treatment of aphasia. Stroke 2001;32:2093-8.
70. Grade C, Redford B, Chrostowski J, et al. Methylphenidate in early post-stroke recovery: a double-blind, placebo-controlled study. Arch Phys Med Rehabil 1998;79:1047-50.
71. Scheidtmann K, Fries W, Muller F, et al. Effect of levodopa in combination with physiotherapy on functional motor recovery after stroke: a prospective, randomised, double-blind study. Lancet 2001;358:787-90.
72. Goldstein LB, Dromerick AW, Good DC, et al. The Amphetamine Enhanced Stroke Recovery (AESR) Trial, 2002 www.strokeconference.org. Accessed March 4, 2002.
73. Goldstein LB, Davis JN. Clonidine impairs recovery of beam-walking in rats. Brain Res 1990;508:305-9.